🇪🇺 LY2189265 in European Union

EMA authorised LY2189265 on 21 November 2014

Marketing authorisation

EMA — authorised 21 November 2014

  • Application: EMEA/H/C/002825
  • Marketing authorisation holder: Eli Lilly Nederland B.V.
  • Local brand name: Trulicity
  • Indication: Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
  • Status: approved

Read official source →

LY2189265 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Diabetes approved in European Union

Frequently asked questions

Is LY2189265 approved in European Union?

Yes. EMA authorised it on 21 November 2014.

Who is the marketing authorisation holder for LY2189265 in European Union?

Eli Lilly Nederland B.V. holds the EU marketing authorisation.